Thalidomide

"Thalidomide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.

Descriptor ID	D013792
MeSH Number(s)	D02.241.223.805.810.800 D03.383.621.808.800 D03.633.100.513.750.750
Concept/Terms	Thalidomide Thalidomide Sedoval Sedoval Thalomid Thalomid

Below are MeSH descriptors whose meaning is more general than "Thalidomide".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Carboxylic Acids [D02.241]
Acids, Carbocyclic [D02.241.223]
Phthalic Acids [D02.241.223.805]
Phthalimides [D02.241.223.805.810]
Thalidomide [D02.241.223.805.810.800]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Piperidines [D03.383.621]
Piperidones [D03.383.621.808]
Thalidomide [D03.383.621.808.800]
Heterocyclic Compounds, Fused-Ring [D03.633]
Heterocyclic Compounds, 2-Ring [D03.633.100]
Isoindoles [D03.633.100.513]
Phthalimides [D03.633.100.513.750]
Thalidomide [D03.633.100.513.750.750]

Below are MeSH descriptors whose meaning is related to "Thalidomide".

Below are MeSH descriptors whose meaning is more specific than "Thalidomide".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Thalidomide" by people in this website by year, and whether "Thalidomide" was a major or minor topic of these publications.

Bar chart showing 21 publications over 16 distinct years, with a maximum of 3 publications in 2004 and 2013

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	1	0	1
2004	2	1	3
2005	0	1	1
2006	1	0	1
2007	1	0	1
2009	1	0	1
2010	0	1	1
2011	1	0	1
2012	0	1	1
2013	1	2	3
2016	1	0	1
2017	1	0	1
2018	2	0	2
2019	0	1	1
2020	0	1	1
2021	0	1	1

Below are the most recent publications written about "Thalidomide" by people in Profiles.

Valentine L, Norris MR, Bielory L. Comparison of structural components and functional mechanisms within the skin vs. the conjunctival surface. Curr Opin Allergy Clin Immunol. 2021 10 01; 21(5):472-479.

View in: PubMed
Swaminathan N, Gupta S, Dourado C. Case Report: IgG multiple myeloma and chronic myeloid leukemia in a single patient. F1000Res. 2020; 9:488.

View in: PubMed
Karadag AS, Parish LC. Sarcoidosis: A great imitator. Clin Dermatol. 2019 May - Jun; 37(3):240-254.

View in: PubMed
Tun HW, Johnston PB, DeAngelis LM, Atherton PJ, Pederson LD, Koenig PA, Reeder CB, Omuro AMP, Schiff D, O'Neill B, Pulido J, Jaeckle KA, Grommes C, Witzig TE. Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma. Blood. 2018 11 22; 132(21):2240-2248.

View in: PubMed
Norris MR, Bielory L. Chronic tearing induced by apremilast. Ann Allergy Asthma Immunol. 2018 09; 121(3):375.

View in: PubMed
Mark TM, Guarneri D, Forsberg P, Rossi A, Pearse R, Perry A, Pekle K, Tegnestam L, Greenberg J, Shore T, Gergis U, Mayer S, Van Besien K, Ely S, Jayabalan D, Sherbenou D, Coleman M, Niesvizky R. A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma. Biol Blood Marrow Transplant. 2017 Jun; 23(6):930-937.

View in: PubMed
Simon AJ, Lev A, Zhang Y, Weiss B, Rylova A, Eyal E, Kol N, Barel O, Cesarkas K, Soudack M, Greenberg-Kushnir N, Rhodes M, Wiest DL, Schiby G, Barshack I, Katz S, Pras E, Poran H, Reznik-Wolf H, Ribakovsky E, Simon C, Hazou W, Sidi Y, Lahad A, Katzir H, Sagie S, Aqeilan HA, Glousker G, Amariglio N, Tzfati Y, Selig S, Rechavi G, Somech R. Mutations in STN1 cause Coats plus syndrome and are associated with genomic and telomere defects. J Exp Med. 2016 07 25; 213(8):1429-40.

View in: PubMed
Ganesan P, Piha-Paul S, Naing A, Falchook G, Wheler J, Janku F, Zinner R, Laday S, Kies M, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer. Invest New Drugs. 2013 Dec; 31(6):1505-13.

View in: PubMed
Ali MS, Starke RM, Jabbour PM, Tjoumakaris SI, Gonzalez LF, Rosenwasser RH, Owens GK, Koch WJ, Greig NH, Dumont AS. TNF-a induces phenotypic modulation in cerebral vascular smooth muscle cells: implications for cerebral aneurysm pathology. J Cereb Blood Flow Metab. 2013 Oct; 33(10):1564-73.

View in: PubMed
Liu H, Gaspari AA, Schleichert R. Use of lenalidomide in treating refractory prurigo nodularis. J Drugs Dermatol. 2013 Mar; 12(3):360-1.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement